Cloud Banner

Pharmaceutical

Image

Middle East and Africa Dyspepsia Drug Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Published Report
  • May 2023
  • MEA
  • 350 Pages
  • No of Tables: 340
  • No of Figures: 52

Middle East and Africa Dyspepsia Drug Market, By Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.

Middle East and Africa Dyspepsia Drug Market

Middle East and Africa Dyspepsia Drug Market Analysis and Insights

The Middle East and Africa dyspepsia drug market is expected to grow in the forecast period due to the increasing prevalence of dyspepsia and the rising adoption of unhealthy lifestyles. The market is also influenced by the increase in the prevalence of metabolic disorders. However, the Middle East and Africa dyspepsia drug market is expected to be hampered by the possible side effects of the drugs used for dyspepsia and the increasing preference for natural and herbal remedies. The growing aging population and rise in drug approval are expected to act as opportunities for market growth. However, stringent regulations and a lack of awareness about dyspepsia among the population is expected to challenge the market growth.

Middle East and Africa Dyspepsia Drug MarketMiddle East and Africa Dyspepsia Drug Market

Data Bridge Market Research analyzes that the Middle East and Africa dyspepsia drug market is expected to grow at a CAGR of 3.0% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in Thousand, Volumes in Units, and Pricing in USD

Segments Covered

Type (Organic Dyspepsia, Non-Ulcer Dyspepsia, Drug Induced Dyspepsia, and Others), Treatment Type (Medication and Surgery), Drug Type (Branded and Generic), Prescription (Without Prescription Drugs and Prescription Drugs), Route of Administration (Oral and Injectable), Gender (Male and Female), End User (Hospitals, Clinics, Homecare settings, Specialty Clinics, Ambulatory Surgical Centers, Academic and Government Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales)

Countries Covered

South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Saudi Arabia, Qatar, and Rest of Middle East and Africa

Market Players Covered

Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others

Market Definition

Dyspepsia, commonly known as indigestion, is the pain and discomfort experienced in the abdomen after eating. It is usually a sign of an underlying condition like GERD (gastroesophageal reflux disease), gallbladder, and ulcer disease. Treatment for dyspepsia depends on the cause and severity. Treating an underlying condition or changing a person's medication will reduce dyspepsia. Dyspepsia is divided into 2 main categories: "organic" and "functional dyspepsia" (FD). Organic causes of dyspepsia are peptic ulcer, gastroesophageal reflux disease, gastric or esophageal cancer, pancreatic or biliary disorders, intolerance to food or drugs, and other infectious or systemic diseases. Functional dyspepsia (dis-PEP-see-uh) is a term for recurring symptoms of an upset stomach that have no obvious cause. Functional dyspepsia is also called non ulcer dyspepsia.

Middle East and Africa Dyspepsia Drug Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

DRIVERS

  • Increasing prevalence of dyspepsia

Dyspepsia, commonly known as indigestion, is a gastrointestinal disorder that affects millions of people in Middle East and Africa. It is a condition that causes discomfort, pain, and a feeling of fullness or bloating in the upper abdomen. Dyspepsia can be caused by a variety of factors such as eating too quickly, consuming spicy or fatty foods, or as a side effect of medication.

The increasing prevalence of dyspepsia is one of the key driving factors for the growth of the dyspepsia drug market. The rising incidence of dyspepsia can be attributed to several factors such as changes in lifestyle, dietary habits, and an aging population. As people age, they are more susceptible to digestive problems, including dyspepsia. With the growing number of older adults, there is a higher demand for dyspepsia drugs.

In addition, different digestive diseases like irritable bowel syndrome, gastroparesis, gastritis, and peptic ulcer disease also cause dyspepsia, due to the increasing prevalence of the mentioned disease. Thus the growing prevalence of dyspepsia and other digestive disorders causing dyspepsia is expected to act as the driver for the market’s growth. The use of dyspepsia drugs for relieving the symptoms of dyspepsia and treating the dyspepsia has the potential to improve patient outcomes and reduce the burden of dyspepsia. Thus, the increasing prevalence of dyspepsia is driving the demand for dyspepsia drugs worldwide to increase the incidence and prevalence of the dyspepsia among population.

  • Rise in the adoption of unhealthy lifestyle

In recent years, there has been a rise in the adoption of unhealthy lifestyles, which has contributed to an increase in the prevalence of dyspepsia. Unhealthy lifestyle choices such as a diet high in processed foods, lack of exercise, and excessive alcohol consumption can all contribute to dyspepsia.

As a result, there has been a corresponding increase in the demand for dyspepsia drugs, as people seek relief from their symptoms. The dyspepsia drug market has responded to this demand with a variety of medications, including proton pump inhibitors, H2 receptor antagonists, and antacids.

The rise in the adoption of unhealthy lifestyles can be attributed to several factors, including changes in dietary habits, increasing stress levels, and a sedentary lifestyle. Modern life is often characterized by long working hours, high levels of stress, and easy access to fast food and other unhealthy options. These factors can contribute to dyspepsia and other related conditions such as gastroesophageal reflux disease (GERD).

In conclusion, dyspepsia is a common condition that can be caused by a variety of factors, including unhealthy lifestyle choices. The rise in the adoption of unhealthy lifestyles has contributed to an increase in the prevalence of dyspepsia, and the demand for effective dyspepsia drugs has correspondingly increased which is expected to act as a driver for the growth of the market.

OPPORTUNITY

  • Growing aging population

The number of people who are 65 and older is expected to reach 1.5 billion by the year 2050, according to estimates, which shows that the world's population is rapidly aging and growing older. People have a higher risk of developing chronic health conditions as they get older. This includes digestive disorders such as dyspepsia, which can occur as a result of aging.

There is a significant opportunity for the expansion of the dyspepsia drug market presented by the growing and aging population. Because more and more people are having problems with their digestive systems, there is a growing need for effective treatments that can reduce the severity of their symptoms and enhance their overall quality of life.

In addition, the treatment of dyspepsia may need to be tailored specifically to the requirements of an aging population. It is possible for older people to have multiple chronic conditions and to be taking multiple medications at the same time, both of which can increase the likelihood of negative drug interactions and side effects. As a result, there is a demand for dyspepsia medications that are both risk-free and effective when administered to older adults. And with aging people also lose their physical and immunity strength which leads to causing an increasing prevalence of several gastro-related diseases including dyspepsia.

Hence increase in the aging population causing dyspepsia and its symptoms and the people's preference for preventive healthcare is expected to act as an opportunity for the growth of the dyspepsia drug market.

RESTRAINT/CHALLENGE

  • Lack of  awareness about dyspepsia among the population

The shortage of skills is already impacting the nation, with an increasing number of people being forced to wait more than six months for their dental treatments. There is a shortage of skilled professionals in the field of Dyspepsia Drug in emerging or developing countries due to technical advancements, basic infrastructure, and several other factors.

The lack of skilled professionals is partly due to the rigorous education and training required to become a dental professional as well as the competitive job market. Moreover, skilled dentists need more formally-trained, licensed dental assistants to help maintain and increase access to oral healthcare to operate and execute advanced technological systems such as dyspepsia drug systems.

The emerging countries lack skilled professionals who cannot operate the new technologies effectively. This might create a challenge in the market for new technologies to emerge as these countries are delaying the onset of technologically driven advancements in the market.

Recent Developments

  • In April 2023, Sanofi announced that it had completed the acquisition of Provention Bio, Inc. This acquisition has helped the company in the expansion of its business in general medicine.
  • In July 2022, ANI Pharmaceuticals, Inc. announced the purchase of four abbreviated new drug applications (ANDAs) from Oakrum Pharma, LLC, a privately owned biopharmaceutical company.

Middle East and Africa Dyspepsia Drug Market Segmentation

The Middle East and Africa dyspepsia drug market is segmented into type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Type

  • Non-Ulcer Dyspepsia
  •  Organic Dyspepsia
  •  Drug Induced Dyspepsia
  •  Others

Based on type, Middle East and Africa dyspepsia drug market is segmented into organic dyspepsia, non-ulcer dyspepsia, drug induced dyspepsia, and others.

Treatment Type

  • Medication
  • Surgery

Based on treatment type, Middle East and Africa dyspepsia drug market is segmented into medication and surgery.

Drug Type

  • Branded
  • Generic

Based on drug type Middle East and Africa dyspepsia drug market is segmented into generic, and branded.

Prescription

  • Without Prescription Drugs
  • Prescription Drugs

Based on prescription, Middle East and Africa dyspepsia drug market is segmented into without prescription drugs and prescription drugs.

Route of Administration

  • Oral
  • Injectable

Based on the route of administration, Middle East and Africa dyspepsia drug market is segmented into oral, and injectable.

Gender

  • Male
  • Female

Based on gender, Middle East and Africa dyspepsia drug market is segmented into male and female.

End User

  • Hospitals
  • Clinics
  • Homecare Settings
  • Specialty Clinics
  • Ambulatory Centers
  • Academic and Government Research Institutes
  • Others

Based on end user, Middle East and Africa dyspepsia drug market is segmented into hospitals, clinics, homecare settings, specialty clinics, ambulatory surgical centers, academic and government research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales

Based on the distribution channel, Middle East and Africa dyspepsia drug market is segmented into direct tenders and retail sales.

Dyspepsia Drug Market

Middle East and Africa Dyspepsia Drug Market Regional Analysis/Insights

The Middle East and Africa dyspepsia drug market is analyzed, and market size insights and trends are provided based on type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.

The countries covered in this market report are the South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Saudi Arabia, Qatar, and Rest of Middle East and Africa.

South Africa is expected to dominate the Middle East and Africa dyspepsia drug market due to the increasing research in the field of dyspepsia drug and development.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Dyspepsia Drug Market Share Analysis

The Middle East and Africa dyspepsia drug market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the market.

Some of the major market players operating in the market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.


SKU-

TABLE 1 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 MIDDLE EAST AND AFRICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 MIDDLE EAST AND AFRICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 MIDDLE EAST AND AFRICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 MIDDLE EAST AND AFRICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 19 MIDDLE EAST AND AFRICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 MIDDLE EAST AND AFRICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 22 MIDDLE EAST AND AFRICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 MIDDLE EAST AND AFRICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 MIDDLE EAST AND AFRICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 29 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 31 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 33 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 37 MIDDLE EAST AND AFRICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 MIDDLE EAST AND AFRICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 MIDDLE EAST AND AFRICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 MIDDLE EAST AND AFRICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 43 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 44 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 MIDDLE EAST AND AFRICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 48 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 MIDDLE EAST AND AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 51 MIDDLE EAST AND AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 MIDDLE EAST AND AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 55 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 MIDDLE EAST AND AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 57 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 MIDDLE EAST AND AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 59 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 61 MIDDLE EAST AND AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 MIDDLE EAST AND AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 64 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 66 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 67 MIDDLE EAST AND AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 68 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 69 MIDDLE EAST AND AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 70 MIDDLE EAST AND AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 71 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 MIDDLE EAST AND AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 74 MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 75 MIDDLE EAST AND AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 76 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 SOUTH AFRICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 SOUTH AFRICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 SOUTH AFRICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 84 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 86 SOUTH AFRICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 87 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 89 SOUTH AFRICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 90 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 92 SOUTH AFRICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 93 SOUTH AFRICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 94 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 95 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 96 SOUTH AFRICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 97 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 99 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 100 SOUTH AFRICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 101 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 102 SOUTH AFRICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 103 SOUTH AFRICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 104 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 105 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 SOUTH AFRICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 107 SOUTH AFRICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 108 SOUTH AFRICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 109 EGYPT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 110 EGYPT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 EGYPT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 EGYPT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 EGYPT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 116 EGYPT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 117 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 119 EGYPT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 120 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 121 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 122 EGYPT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 123 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 125 EGYPT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 126 EGYPT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 127 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 129 EGYPT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 130 EGYPT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 131 EGYPT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 132 EGYPT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 133 EGYPT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 134 EGYPT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 135 EGYPT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 136 EGYPT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 137 EGYPT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 138 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 EGYPT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 140 EGYPT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 141 EGYPT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 142 BAHRAIN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 143 BAHRAIN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 144 BAHRAIN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 BAHRAIN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 BAHRAIN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 149 BAHRAIN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 150 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 152 BAHRAIN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 153 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 155 BAHRAIN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 156 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 158 BAHRAIN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 159 BAHRAIN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 160 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 161 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 162 BAHRAIN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 163 BAHRAIN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 164 BAHRAIN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 165 BAHRAIN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 166 BAHRAIN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 167 BAHRAIN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 168 BAHRAIN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 169 BAHRAIN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 170 BAHRAIN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 171 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 BAHRAIN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 173 BAHRAIN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 174 BAHRAIN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 175 U.A.E DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 176 U.A.E DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 177 U.A.E MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 U.A.E DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 179 U.A.E ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 180 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 182 U.A.E PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 183 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 184 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 185 U.A.E H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 186 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 188 U.A.E GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 189 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 190 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 191 U.A.E ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 192 U.A.E NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 193 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 195 U.A.E PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 196 U.A.E DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 U.A.E DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 198 U.A.E DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 199 U.A.E ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 200 U.A.E DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 201 U.A.E FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 202 U.A.E MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 203 U.A.E DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 204 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 U.A.E HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 206 U.A.E DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 207 U.A.E RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 208 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 209 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 SAUDI ARABIA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 211 SAUDI ARABIA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 212 SAUDI ARABIA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 215 SAUDI ARABIA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 216 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 217 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 218 SAUDI ARABIA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 219 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 221 SAUDI ARABIA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 222 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 223 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 224 SAUDI ARABIA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 225 SAUDI ARABIA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 227 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 228 SAUDI ARABIA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 229 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 231 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 232 SAUDI ARABIA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 233 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 234 SAUDI ARABIA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 235 SAUDI ARABIA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 236 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 237 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 238 SAUDI ARABIA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 239 SAUDI ARABIA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 240 SAUDI ARABIA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 241 KUWAIT DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 242 KUWAIT DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 243 KUWAIT MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 244 KUWAIT DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 KUWAIT ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 248 KUWAIT PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 249 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 251 KUWAIT H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 252 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 253 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 254 KUWAIT GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 255 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 256 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 257 KUWAIT ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 258 KUWAIT NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 259 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 261 KUWAIT PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 262 KUWAIT DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 263 KUWAIT DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 264 KUWAIT DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 265 KUWAIT ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 266 KUWAIT DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 267 KUWAIT FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 268 KUWAIT MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 269 KUWAIT DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 270 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 271 KUWAIT HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 272 KUWAIT DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 273 KUWAIT RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 OMAN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 275 OMAN DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 OMAN MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 OMAN DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 OMAN ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 279 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 280 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 281 OMAN PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 282 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 284 OMAN H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 285 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 286 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 287 OMAN GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 288 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 289 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 290 OMAN ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 291 OMAN NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 292 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 293 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 294 OMAN PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 295 OMAN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 296 OMAN DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 297 OMAN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 298 OMAN ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 299 OMAN DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 300 OMAN FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 301 OMAN MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 302 OMAN DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 303 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 304 OMAN HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 305 OMAN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 306 OMAN RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 307 QATAR DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 308 QATAR DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 309 QATAR MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 310 QATAR DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 311 QATAR ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 312 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 313 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 314 QATAR PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 315 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 316 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 317 QATAR H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 318 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 319 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 320 QATAR GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 321 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 322 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 323 QATAR ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 324 QATAR NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 325 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 326 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 327 QATAR PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 328 QATAR DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 329 QATAR DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 330 QATAR DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 331 QATAR ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 332 QATAR DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 333 QATAR FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 334 QATAR MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 335 QATAR DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 336 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 337 QATAR HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 338 QATAR DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 339 QATAR RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 340 REST OF MIDDLE EAST AND AFRICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Middle East and Africa Dyspepsia Drug Market is projected to grow at a CAGR of 3.0% during the forecast period by 2030.
The Middle East and Africa Dyspepsia Drug Market is segmented on the basis of type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.
The major players in the Middle East and Africa Dyspepsia Drug Market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.
The countries covered in the Middle East and Africa Dyspepsia Drug Market are South Africa, Egypt, Bahrain, United Arab Emirates, Kuwait, Oman, Saudi Arabia, Qatar, and Rest of Middle East and Africa.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials